93 results
SPYRAL HTN-OFF MED Pivotal: Efficacy of Catheter-Based Renal Denervation in the Absence of Antihypertensive Medications
04 Apr 2020
The SPYRAL HTN-OFF MED Pivotal trial is a sham controlled randomized study examining the efficacy and safety of renal artery denervation (RDN) compared to a sham group, and the primary endpoint was the reduction in the blood pressure of subjects with uncontrolled hypertension not on antihypertensive...
Author
Optimise treatment of hypertension with new European guidelines
What is the most up to date definition of hypertension? What target blood pressure should you aim for in patients with hypertension and which treatments should be given firstline to lower blood pressure in these patients? Darren Mylotte and Felix Mahfoud discuss the new European Hypertension...
Future of renal denervation
It has been a year since the most recent sham controlled trials of renal denervation (RDN) were presented at EuroPCR. Join Felix Mahfoud as he talks to Roland Schmieder and Flavio Ribichini about what they have learned since. Find out what has changed in terms of...
Truths and myths about renal denervation
A session at EuroPCR 2019 was dedicated to the truths and myths surrounding renal denervation. Does ablation location matter? Is safe and successful denervation as simple as measuring ablation depth? Should renal denervation be avoided in patients with isolated hypertension? Is the effect of renal denervation...
Ultrasound renal denervation: RADIANCE-HTN SOLO results
What is the latest evidence on the efficacy and safety of ultrasound renal denervation in treating hypertension? Reintroducing antihypertensive medication to patients previously treated with renal denervation is under discussion as Felix Mahfoud, Michel Azizi and Ajay Kirtane consider the 6-month results from the RADIANCE-HTN SOLO...
Renal denervation for hypertension treatment: What have we learnt recently?
With the results from 3 recent randomised trials and with 2 technologies, Michel Azizi (France) asks Felix Mahfoud (Germany) about the return of renal denervation not only as a treatment of resistant hypertension but also its use in non-end-stage disease and its application in other fields....
Catheter-based renal denervation – Back in routine clinical practice?
23 May 2019 – From EuroPCR 2019
Consult this session on catheter-based renal denervation to learn about recent studies, the "ideal patients", the pre-procedural planning and procedural aspects of renal denervation, and more!
Interventional neuromodulation – Indications beyond hypertension
23 May 2019 – From EuroPCR 2019
Consult this session on interventional neuromodulation to learn more about the importance of sympathetic overactivity in the pathophysiology of heart failure, arrhythmias, and renal insufficiency and appraise the available and upcoming evidence.
RADIANCE-HTN SOLO: six-month results of renal denervation in patients on medications using the ReCor Paradise endovascular ultrasound system in a randomised, blinded, sham-controlled study
23 May 2019 – From EuroPCR 2019
Consult this session to learn all about the latest results from the RADIANCE-HTN SOLO cohort at the 6-month time point to assess efficacy of renal denervation in patients after medication titration.
ON MED, OFF MED, now what? Future of renal denervation
23 May 2019 – From EuroPCR 2019
Consult this session on renal denervation to gain insights on the future of renal denervation and to learn about the latest results of SPYRAL HTN clinical program.
